title: Hypothesis driven development of new adjuvants: short peptides as immunomodulators.
abstract: To date, vaccinations have been one of the key strategies in the prevention and protection against infectious pathogens. Traditional vaccines have well-known limitations such as safety and efficacy issues, which consequently deems it inappropriate for particular populations and may not be an effective strategy against all pathogens. This evidence highlights the need to develop more efficacious vaccination regiments. Higher levels of protection can be achieved by the addition of immunostimulating adjuvants. Many adjuvants elicit strong, undefined inflammation, which produces increased immunogenicity but may also lead to undesirable effects. Hypothesis driven development of adjuvants is needed to achieve a more specific and directed immune response required for optimal and safe vaccine-induced immune protection. An example of such hypothesis driven development includes the use of short immunomodulating peptides as adjuvants. These peptides have the ability to influence the immune response and can be extrapolated for adjuvant use, but requires further investigation.
authors.affiliation: Special Pathogens Program; National Microbiology Laboratory; Public Health Agency of Canada; Winnipeg, MB Canada; Department of Immunology; University of Manitoba; Winnipeg, MB Canada.
authors.forename: Jessica C
authors.initials: JC
authors.lastname: Dong
authors.forename: Gary P
authors.initials: GP
authors.lastname: Kobinger
mesh_terms: D000276:Adjuvants, Immunologic / Q000302:isolation & purification* / Q000494:pharmacology*; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D010455:Peptides / Q000302:isolation & purification / Q000494:pharmacology
chemical_list: D000276:Adjuvants, Immunologic; D010455:Peptides
keywords: adjuvant development; immunomodulating peptides; novel adjuvants; peptide adjuvants; vaccine development
references.citation: Adv Genet. 2005;55:25-40
references.pmid: 16291211
references.citation: Amino Acids. 2007 Nov;33(4):703-7
references.pmid: 17077961
references.citation: Curr Pharm Des. 2009;15(28):3283-9
references.pmid: 19860677
references.citation: Curr Opin Immunol. 2009 Feb;21(1):23-9
references.pmid: 19246182
references.citation: Expert Rev Vaccines. 2011 Apr;10(4):447-62
references.pmid: 21506643
references.citation: Semin Immunol. 2010 Jun;22(3):155-61
references.pmid: 20488726
references.citation: J Leukoc Biol. 2005 Apr;77(4):451-9
references.pmid: 15569695
references.citation: J Med Microbiol. 2012 Jul;61(Pt 7):889-894
references.pmid: 22322337
references.citation: Expert Rev Vaccines. 2011 Apr;10(4):539-50
references.pmid: 21506650
references.citation: J Exp Med. 2011 Nov 21;208(12):2357-66
references.pmid: 22065672
references.citation: Nat Rev Immunol. 2011 Nov 04;11(12):865-72
references.pmid: 22051890
references.citation: Discov Med. 2011 Sep;12(64):195-204
references.pmid: 21955847
references.citation: Vaccine. 1997 Aug-Sep;15(12-13):1364-71
references.pmid: 9302746
references.citation: Clin Infect Dis. 2011 Aug 1;53(3):296-302
references.pmid: 21765081
references.citation: Methods Mol Med. 2006;127:363-74
references.pmid: 16988466
references.citation: Curr Opin Mol Ther. 2003 Apr;5(2):98-106
references.pmid: 12772497
references.citation: Expert Rev Vaccines. 2012 Feb;11(2):189-209
references.pmid: 22309668
references.citation: Lancet Infect Dis. 2012 Jan;12(1):36-44
references.pmid: 22032844
references.citation: Ther Deliv. 2011 Aug;2(8):1057-77
references.pmid: 22826868
references.citation: Immunol Res. 2008;42(1-3):219-32
references.pmid: 19066740
references.citation: Science. 2002 Aug 9;297(5583):937-9
references.pmid: 12169712
references.citation: Cell Immunol. 2011;269(1):5-9
references.pmid: 21477796
references.citation: Nat Rev Immunol. 2009 Apr;9(4):287-93
references.pmid: 19247370
references.citation: J Med Microbiol. 2012 Jul;61(Pt 7):927-934
references.pmid: 22174375
references.citation: Immunol Rev. 2011 Jan;239(1):62-84
references.pmid: 21198665
references.citation: Adv Drug Deliv Rev. 1998 Jul 6;32(3):155-172
references.pmid: 10837642
references.citation: Nat Biotechnol. 2006 Dec;24(12):1551-7
references.pmid: 17160061
references.citation: PLoS One. 2012;7(8):e43802
references.pmid: 22937099
references.citation: Clin Exp Immunol. 1985 Jul;61(1):143-51
references.pmid: 3876178
references.citation: Expert Rev Vaccines. 2011 Apr;10(4):471-86
references.pmid: 21506645
references.citation: Ann N Y Acad Sci. 2010 Dec;1213:46-61
references.pmid: 20946578
references.citation: Hum Vaccin. 2006 Mar-Apr;2(2):45-53
references.pmid: 17012886